Trinity Biotech
TRIB
24 hedge funds and large institutions have $22.6M invested in Trinity Biotech in 2020 Q4 according to their latest regulatory filings, with 6 funds opening new positions, 6 increasing their positions, 8 reducing their positions, and 5 closing their positions.
217% more call options, than puts
Call options by funds: $460K | Put options by funds: $145K
78% more capital invested
Capital invested by funds: $12.7M → $22.6M (+$9.89M)
20% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 5
4% more funds holding
Funds holding: 23 → 24 (+1)
0% less ownership
Funds ownership: 0.05% → 0.05% (-0%)
25% less repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 8
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$763K |
| 2 |
Two Sigma Investments
New York
|
+$424K |
| 3 |
Acadian Asset Management
Boston,
Massachusetts
|
+$362K |
| 4 |
Millennium Management
New York
|
+$266K |
| 5 |
NA
Navellier & Associates
Reno,
Nevada
|
+$215K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Stonehill Capital Management
New York
|
-$1.23M |
| 2 |
HA
Heartland Advisors
Milwaukee,
Wisconsin
|
-$995K |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$173K |
| 4 |
HAIM
Hunter Associates Investment Management
Pittsburgh,
Pennsylvania
|
-$116K |
| 5 |
Morgan Stanley
New York
|
-$108K |
TRIB Hedge Fund Activity: Q4 2020 in Review
24 of the 5,676 institutional investors tracked by Wall St. Rank reported a position in Trinity Biotech (TRIB) for Q4 2020, worth a combined $22.6M — up 78% from $12.7M a quarter earlier.
Buyers outnumbered sellers: 6 funds opened new TRIB positions and 5 closed out — a net gain of 1 holder — while 6 added to existing stakes and 8 trimmed.
The largest buyer was Renaissance Technologies, adding an estimated $763K. The largest seller was Stonehill Capital Management, cutting an estimated $1.23M.
- 24 institutional investors held Trinity Biotech (TRIB) as of Q4 2020, up from 23 in Q3 2020.
- Funds reported $22.6M of Trinity Biotech stock for Q4 2020, up 78% quarter-over-quarter.
- 6 funds opened new Trinity Biotech positions in Q4 2020 and 5 closed out, a net change of +1 holder.
- The largest Trinity Biotech buyer in Q4 2020 was Renaissance Technologies, an estimated $763K added.
- The largest Trinity Biotech seller in Q4 2020 was Stonehill Capital Management, an estimated $1.23M sold.
Based on aggregated 13F filings for Q4 2020.